

# Clinical Implications of Diagnosing Irritable Bowel Syndrome

Citation for published version (APA):

Keszthelyi, D., & Ringel, Y. (2017). Clinical Implications of Diagnosing Irritable Bowel Syndrome: Do All Roads Need to Lead to Rome? *American Journal of Gastroenterology*, 112(6), 900-902.  
<https://doi.org/10.1038/ajg.2017.115>

## Document status and date:

Published: 01/06/2017

## DOI:

[10.1038/ajg.2017.115](https://doi.org/10.1038/ajg.2017.115)

## Document Version:

Publisher's PDF, also known as Version of record

## Document license:

Taverne

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

see related article on page 892

# Clinical Implications of Diagnosing Irritable Bowel Syndrome: Do All Roads Need to Lead to Rome?

Daniel Keszthelyi, MD, PhD<sup>1</sup> and Yehuda Ringel, MD<sup>2,3</sup>

**Abstract: Irritable bowel syndrome (IBS) is one of the most common diagnoses made by healthcare providers. Yet the majority of patients with IBS are undiagnosed. The study by Sayuk *et al.* allows insight into the characteristics of different patient groups, e.g., with and without a formal diagnosis of diarrhea predominant IBS (IBS-D). We discuss the questions raised by this study regarding the importance of making a confident diagnosis, conveying it to patients and their implications for clinical practice.**

*Am J Gastroenterol* 2017; 112:900–902; doi:10.1038/ajg.2017.115

Abdominal pain and diarrhea are the leading gastrointestinal (GI) symptoms prompting ambulatory visits in the United States with more than 27 million ambulatory, emergency department, and hospital outpatient clinic visits per year. Abdominal pain and diarrhea are also common leading GI diagnoses in the ambulatory setting, with “abdominal pain” being the most common (over 16.6 million per year) and “diarrhea” the ninth most common (over 2.6 million per year). Interestingly, the diagnoses of abdominal pain and diarrhea are more common than the diagnosis of irritable bowel syndrome (IBS; tenth most common diagnosis with 2.4 million diagnoses per year) (1). The fact that these diagnoses are so often made does not come as a surprise when considering the high prevalence of GI symptoms in the general population. Although epidemiological data are scarce (2), the available numbers indicate that a significant portion of the US population—42% of adults (3) and 23% of children and adolescents (4)—experience GI symptoms that correspond with at least one of 20 functional GI disorders (FGIDs), including IBS. However, more than half of the individuals with functional bowel symptoms do not seek medical care for their symptoms (5).

These individuals are often referred to as non-patient individuals with FGIDs.

In this issue of the journal, Sayuk *et al.* report their findings from an online survey conducted in 1,924 individuals from a general US population who had previously participated in various surveys and had indicated having GI symptoms. Individuals were excluded if they reported having habitual constipation or rectal blood loss in the month prior to participating in the survey. The authors found that 1,094 (56.9%) of the respondents met the Rome III criteria for IBS-D and received a formal diagnosis from their health care provider. The other 830 (43.1%) individuals fulfilled the Rome III criteria for the disorder (IBS-D), but had never received a formal diagnosis. Furthermore, over half (53%) of these undiagnosed individuals have never spoken to a physician about their abdominal symptoms, and therefore, have never received a formal diagnosis (6). Given this considerable proportion, the question arises what factors drive individuals experiencing abdominal symptoms compatible with IBS to consult their health care providers about these symptoms? While most studies have repeatedly shown that abdominal symptom severity is an important determinant in this regard, discrepant findings have been reported for the exact role for psychological factors (7–11). This category of non-patient individuals therefore may represent a population characterized by mild severity of IBS symptoms. These individuals are probably able to cope and manage their symptoms adequately without any additional involvement of the health care system. For this group of non-patients, education via non-formal routes (lay media, family, and peers etc.) seems appropriate and probably sufficient. A formal diagnosis therefore does not appear to be necessary.

In addition, the study by Sayuk *et al.* (6) allows further insight into another category of patients: those whose symptoms were compatible with IBS-D who had sought the advice of a health-care professional, but have not received a formal diagnosis. This population represents 47% (390/830) of all subjects surveyed without a formal diagnosis. This number seems surprisingly

<sup>1</sup>Division of Gastroenterology-Hepatology, Department of Internal Medicine, Maastricht University Medical Center, Maastricht, The Netherlands; <sup>2</sup>Division of Gastroenterology, Rabin Medical Center, Petah Tikva, Israel; <sup>3</sup>Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA. **Correspondence:** Yehuda Ringel, MD, Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, 4107 BiInformatomics Bldg, CB# 7080, 130 Mason Farm RD, Chapel Hill, North Carolina 27599-7080, USA. E-mail: ringel@med.unc.edu

Received 15 December 2016; accepted 13 March 2017

high. After all, an individual with IBS-symptoms seeking advice from a healthcare professional, for instance due to the severity of their symptoms, would rightfully expect to receive a diagnosis and appropriate advice in terms of treatment and management of their symptoms. Such a formal diagnosis helps initiate a dialogue between patient and healthcare provider with regards to insight into triggering factors and treatment options—so argue Sayuk *et al.* (6). With regards to treatment options, a variety of non-medicinal approaches (e.g., dietary and behavioral interventions) have shown to be effective treatments for IBS symptoms and many of the patients prefer and do well with these approaches. In addition, it is important to remember that demonstrated therapeutic effectiveness with a specific intervention in IBS patients does not guarantee similar effectiveness in non-patients or patients without a formal diagnosis of IBS (12). Above all, IBS patients often simply ask for explanations and expect to be educated about their disease, rather than a prescription for medication to cure or alleviate their symptoms (13). Furthermore, with regard to medications, a multinational study has shown that, although over 60% of patients with abdominal cramping and pain use some form of medication, the majority of the patients prefer over-the-counter medicines over prescription drugs (14). Thus, decisions regarding therapeutic approaches and specifically pharmacotherapy should be done on an individual basis, based on patients' predominant symptoms, illness severity, and patients' preference.

Another intriguing finding by Sayuk *et al.* (6) sheds light on an apparent disconnect between the treating physician and the patient having symptoms compatible with IBS-D; 45% of patients without a formal diagnosis who have had their symptoms for over 10 years and have seen a gastroenterologist, report that they have indeed never received the diagnosis of IBS-D. How is this possible? Are gastroenterologists not confident in making the diagnosis of IBS-D? Were patients given an alternative diagnosis? Or is it a failure to explicitly communicate the diagnosis to patients? In fact, a small study from Iceland using telephone interviews showed similar findings: only one out of five individuals with IBS symptoms was formally diagnosed with IBS, even though more than half of them saw a physician because of their GI symptoms. Remarkably, these results were irrespective of whether the patients fulfilled the Manning or Rome III criteria for IBS (15).

From the providers' perspective, we know from earlier studies that general practitioners generally do not use the Rome criteria for IBS diagnosis but rather rely on a pragmatic approach based on clinical experience, judgment, and knowledge about the patient (16–18). We also know that there is considerable difference between the various symptom-based diagnostic criteria (e.g., Rome III and the less inclusive Rome IV), and that this has significant effects on the prevalence numbers for IBS (19). While the use of new and improved Rome IV criteria should be encouraged among all health care providers, certainty and confidence in making a positive diagnosis of IBS is definitely warranted, regardless of which diagnostic criterion one is most accustomed to using. Indeed, the revised Rome criteria were adjusted by clarifying the language, updating the definition, and including the option of minimal laboratory testing, with the intention to make

it easier for doctors to diagnose IBS (20). However, uncertainty is almost inherent to a symptom-based diagnosis and most community providers still believe that IBS is a diagnosis of exclusion rather than using positive symptom-based criteria to support the diagnosis (21). This approach—or lack of one—is time consuming and costly for the health care system. In regard to this, a recent study suggests that when gastroenterologists use uncertain language in diagnosing patients with FGIDs, this can contribute to patient discard of diagnoses and leads to unnecessary additional studies, endoscopic investigations and repeat consultations (22).

From the patients' perspective, previous studies have shown that the majority of IBS patients felt that they are insufficiently informed on their condition, and were not provided with an adequate explanation for their symptoms (23). This seems particularly relevant since patients may often have considerable misconceptions about IBS. For instance, in a study by Lacy *et al.*, 40.6% of IBS patients thought that colonoscopy can diagnose IBS, and one in seven patients stated that IBS turns into cancer (24). Therefore, in addition to making a clear and confident diagnosis, an effective management strategy must also involve addressing disease-specific fears and concerns and tailoring individual therapeutic approaches while setting mutually reasonable goals and expectations. Indeed, it has been shown that only satisfaction with the physician-patient relationship discriminated between IBS subjects who sought continued consultation with a physician vs. those who did not (8).

What does this all add up to? Apparently we are not doing a good job at diagnosing IBS—or at least communicating and explaining the diagnosis to patients. If so, it could be due to the lack of time for effective communication with the patient, but it could also be due to lack of understanding of IBS or feeling uncomfortable making the diagnosis by the providers themselves. Regardless of the source of the problem, there is still work to be done, by gastroenterologists and their general practitioner colleagues, on improving ways to make a confident diagnosis of IBS and explaining IBS to patients in an effective and convincing way. Given the current restraints on health care systems and limited time in terms of consultations, attempts should be made to establish patient self-help measures for development of better coping and self-empowerment techniques using comprehensive multimedia education material. These approaches have indeed been shown to be efficacious therapeutic tools (25). Digital technology approaches can offer solutions for providing information and insight, engaging patients with or without formal diagnosis into being more health-conscious and potentially improving effective communication between patients and their providers (26).

The broader implications of the findings by Sayuk *et al.* (6) are that they highlight the importance of (i) educating non-patients and patients about IBS (and other FGIDs) symptoms regardless of whether they have sought medical attention, in order to increase common knowledge and clear misconceptions; (ii) and indeed when medical help is required, physicians need to feel confident in making the diagnosis and conveying it effectively to their patients. This should increase our ability to identify patients who are likely to gain from consultation and tailoring of an appropriate

diagnostic and symptom management plan, while avoiding long-term suffering from chronic GI symptoms and/or entering endless rounds of investigations and explanations.

#### CONFLICT OF INTEREST

**Guarantor of the article:** Yehuda Ringel, MD.

**Specific author contributions:** Drafting the manuscript and approving the final draft submitted: both authors.

**Financial support:** None.

**Potential competing interests:** None.

#### REFERENCES

1. Peery AF, Crockett SD, Barritt AS *et al*. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. *Gastroenterology* 2015;149:1731–1741, e3.
2. Corazzari E. Definition and epidemiology of functional gastrointestinal disorders. *Best Pract Res Clin Gastroenterol* 2004;18:613–31.
3. Halder SL, Locke GR 3rd, Schleck CD *et al*. Natural history of functional gastrointestinal disorders: a 12-year longitudinal population-based study. *Gastroenterology* 2007;133:799–807.
4. Lewis ML, Palsson OS, Whitehead WE *et al*. Prevalence of functional gastrointestinal disorders in children and adolescents. *J Pediatr* 2016;177:39–43, e3.
5. Drossman DA, Li Z, Andruzzi E *et al*. U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. *Dig Dis Sci* 1993;38:1569–80.
6. Sayuk GS, Wolf R, Chang L. Comparison of symptoms, healthcare utilization, and treatment in diagnosed and undiagnosed individuals with diarrhea-predominant irritable bowel syndrome. *Am J Gastroenterol* 2017;112:892–99 (this issue).
7. Koloski NA, Talley NJ, Boyce PM. Predictors of health care seeking for irritable bowel syndrome and nonulcer dyspepsia: a critical review of the literature on symptom and psychosocial factors. *Am J Gastroenterol* 2001;96:1340–9.
8. Koloski NA, Talley NJ, Huskic SS *et al*. Predictors of conventional and alternative health care seeking for irritable bowel syndrome and functional dyspepsia. *Aliment Pharmacol Ther* 2003;17:841–51.
9. Lee V, Guthrie E, Robinson A *et al*. Functional bowel disorders in primary care: factors associated with health-related quality of life and doctor consultation. *J Psychosom Res* 2008;64:129–38.
10. Ringstrom G, Abrahamsson H, Strid H *et al*. Why do subjects with irritable bowel syndrome seek health care for their symptoms? *Scand J Gastroenterol* 2007;42:1194–203.
11. Williams RE, Black CL, Kim HY *et al*. Determinants of healthcare-seeking behaviour among subjects with irritable bowel syndrome. *Aliment Pharmacol Ther* 2006;23:1667–75.
12. Ringel-Kulka T, McRorie J, Ringel Y. Multi-Center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the benefit of the probiotic *Bifidobacterium infantis* 35624 in non-patients with symptoms of abdominal discomfort and bloating. *Am J Gastroenterol* 2016;112:145–51.
13. Dancy CP, Backhouse S. Towards a better understanding of patients with irritable bowel syndrome. *J Adv Nurs* 1993;18:1443–50.
14. Quigley EM, Locke GR, Mueller-Lissner S *et al*. Prevalence and management of abdominal cramping and pain: a multinational survey. *Aliment Pharmacol Ther* 2006;24:411–9.
15. Olafsdottir LB, Gudjonsson H, Jonsdottir HH *et al*. Irritable bowel syndrome: physicians' awareness and patients' experience. *World J Gastroenterol* 2012;18:3715–20.
16. Gladman LM, Gorard DA. General practitioner and hospital specialist attitudes to functional gastrointestinal disorders. *Aliment Pharmacol Ther* 2003;17:651–4.
17. Longstreth GF, Burchette RJ. Family practitioners' attitudes and knowledge about irritable bowel syndrome: effect of a trial of physician education. *Fam Pract* 2003;20:670–4.
18. Thompson WG, Heaton KW, Smyth GT *et al*. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. *Gut* 2000;46:78–82.
19. Palsson OS, van Tilburg M, Simren M *et al*. Population prevalence of Rome III and Rome IV Irritable Bowel Syndrome (IBS) in the United States (US), Canada and the United Kingdom (UK). *United European Gastroenterol J* 2016;2(Supplement 1):A34.
20. Lacy BE. Perspective: An easier diagnosis. *Nature* 2016;533:S107.
21. Spiegel BM, Farid M, Esrailian E *et al*. Is irritable bowel syndrome a diagnosis of exclusion?: A survey of primary care providers, gastroenterologists, and IBS experts. *Am J Gastroenterol* 2010;105:848–58.
22. Linedale EC, Chur-Hansen A, Mikocka-Walus A *et al*. Uncertain diagnostic language affects further studies, endoscopies, and repeat consultations for patients with functional gastrointestinal disorders. *Clin Gastroenterol Hepatol* 2016;14:1735–1741, e1.
23. Dhaliwal SK, Hunt RH. Doctor-patient interaction for irritable bowel syndrome in primary care: a systematic perspective. *Eur J Gastroenterol Hepatol* 2004;16:1161–6.
24. Lacy BE, Weiser K, Noddin L *et al*. Irritable bowel syndrome: patients' attitudes, concerns and level of knowledge. *Aliment Pharmacol Ther* 2007;25:1329–41.
25. Zia JK, Barney P, Cain KC *et al*. A Comprehensive self-management irritable bowel syndrome program produces sustainable changes in behavior after 1 Year. *Clin Gastroenterol Hepatol* 2016;14:212–9, e1-2.
26. Spiegel B. 2015 American Journal of Gastroenterology Lecture: How digital health will transform gastroenterology. *Am J Gastroenterol* 2016;111:624–30.